← ANALYST RATINGS · TIPRANKS
Vanda (VNDA): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $13.25, the highest $20.00, the lowest $10.00. The average is +228.8% from the last price of $4.03.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | −0.7% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | −0.7% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | −0.7% | Upgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Hold | −0.7% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +11.7% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $20.00 | Buy | +396.3% | Reiterated | 05.10.26on TipRanks 06:55 | −1.8%next day −1.9% · 5 days −1.3% | ↗ |
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $10.00 | Buy | +148.1% | Initiated | 23.09.26on TipRanks Sep 30 05:50 | −2.5%next day −1.1% · 5 days −1.9% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $17.00 → $12.00−29.4% | Buy | +197.8% | Initiated | 10.08.26on TipRanks 08:35 | +0.4%next day −1.5% · 5 days +4.8% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $11.00 | Buy | +173.0% | Reiterated | 06.08.26on TipRanks Aug 7 14:25 | +0.7%next day −2.9% · 5 days −2.9% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $5.00 → $7.50+50.0% | Hold | +86.1% | Reiterated | 31.12.25on TipRanks 05:10 | +26.2%next day −6.6% · 5 days −17.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vanda
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.25 at a price of $4.91 (+169.9%); now: $13.25 at $4.03 (+228.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 6 | 6 | 5 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.68 (from $-0.83 to $-0.58). Last quarter: $-1.04.
Sales
Next quarter’s sales estimate — $69M (from $61M to $76M). Last quarter: $51M.
Best top-analyst consensus in the sector · Healthcare
About Vanda
- CEO: Mihael H. Polymeropoulos
- Employees: 533
- 2200 Pennsylvania Avenue NW, Washington, DC, 20037, US
- www.vandapharma.com
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Data from the stock’s TipRanks forecast page, read 78 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗